## **RBL Bank**

Refer to important disclosures at the end of this report

# Management saga could delay business normalization story

In a surprising turn of events, the RBI has appointed its chief general manager, Mr Yogesh Dayal, as an additional director on RBL's board for two years; current MD & CEO Mr Vishwavir Ahuja has gone on medical leave; and Executive Director Mr Rajeev Ahuja has been elevated as interim MD & CEO for a smooth transition. Here are our views and key takeaways from management's call:

- Management did not provide satisfactory reasons for the RBI's appointment of its official as an additional director on the bank's board and the sudden management rejig. But we believe that the RBI's long-term discomfort with 1) the unsecured heavy asset-side construct ((MFI + Cards at 31%) creating asset quality risks as seen during Covid and 2) poor compliance with its directives (about risk management/governance/succession) could have possibly led to its swift intervention, apart from ensuring a smooth management transition and comforting the stakeholders.
- Management emphasized that the change in the top management/board is not due to any asset quality issues/divergence and that recovery trends are largely in line with expectations, barring in MFI. Management reiterated its guidance to bring down NNPAs to below 2% from current 2.1% by improving PCR and achieving exit RoA of 1% by Q4. The medium to long-term strategy to build the retail deposit base and diversify the asset book toward a more secured portfolio, including mortgages, will continue and possibly be accelerated.
- The Nomination and Remuneration Committee (NRC) under the oversight of the board will search and recommend a candidate to replace Mr Vishwavir Ahuja in due course, which could typically include internal/external candidates. Mr Rajeev Ahuja (interim MD & CEO) has expressed his interest in the permanent MD & CEO candidature.
- RBL carries a liquidity buffer of Rs120-130bn (16-17% of deposit base) to deal with the initial deposit run-down scare amid the turn of events, which could be limited. Management believes that it has built a reasonably strong retail deposit franchise in past three years after the deposit scare in Mar'19 Yes Bank saga and is now battle-tested to deal with any eventuality.
- Our view: We believe, in order to comfort investors, more explanation will be required from management to justify the sudden exit of Mr Vishwavir Ahuja nearly six months before his term ends (Jun'22) and the RBI's intervention (typically seen in weak banks like Ujjivan, Dhanlaxmi, LVB, J&K Bank). We believe the story will unfold in due course. That said, we draw some comfort from the appointment of Mr Rajeev Ahuja (part of the turnaround journey) as interim MD & CEO, healthy liquidity buffers/capital ratios (Tier I at 15.5%) and management's strategic intent to change the portfolio mix toward secured assets. However, near/medium-term business/asset quality dislocation is inevitable. Thus, we cut our earnings estimates for F22/FY23/FY24 by 176%/13%/12%. We also cut our P/ABV multiple to 0.7x Dec'23E from 0.9x. Accordingly, we cut the TP to Rs165 from Rs215, given lower RoE (8-10% over FY23-24E vs. earlier 9-11%) and near-term management uncertainty. Retain Hold with UW in EAP. We will keep an eye on any further development at the bank.

## Please see our sector model portfolio (Emkay Alpha Portfolio): BFSI-Banks (Page 6)

## Financial Snapshot (Standalone)

	, ,					Source: Bloomber
(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E	This report is solely
Net income	55,398	58,453	63,246	66,941	73,609	following person(s) a of the recommendati
Net profit	5,057	5,079	(920)	10,071	14,311	Anand Dama
EPS (Rs)	10.8	9.2	(1.5)	16.8	23.9	anand.dama@er
ABV (Rs)	207.1	211.9	196.9	214.2	235.8	+91 22 6624 248
RoA (%)	0.6	0.5	(0.1)	1.0	1.2	
RoE (%)	5.6	4.4	(0.7)	7.7	10.1	
PE (x)	16.0	18.8	(112.5)	10.3	7.2	
P/ABV	0.8	0.8	0.9	0.8	0.7	



СМР	Target Price
Rs 173 as of (December 26, 2021)	Rs 165 (▼) 12 months
Rating	Upside
HOLD (∎)	(4.6) %

## Change in Estimates

•				
EPS Chg F	Y22E/FY	′23E (9	%)	-176/-13
Target Pric	e change	e (%)		-23%
Target Peri	od (Mont	hs)		12
Previous R	есо			HOLD
Emkay vs	Consens	sus		
	EPS E	stimat	es	
		F	Y22E	FY23E
Emkay			(1.5)	16.8
Consensus			2.7	23.1
Mean Cons	ensus T	P (12N	1)	Rs 225
Stock Deta	uils			
Bloomberg	Code			RBK IN
Face Value	: (Rs)			10
Shares out	standing	(mn)		599
52 Week H	/L		2	274 / 156
M Cap (Rs	bn/USD	bn)	1	04 / 1.38
Daily Avg V	/olume (r	nos.)	10	,159,390
Daily Avg T	urnover	(US\$ r	nn)	26.5
Sharehold	ing Patte	ern Se	p '21	
Promoters			-	-%
FIIs				29.2%
DIIs				22.3%
Public and	Others			48.5%
Price Perfe	ormance	1		
(%)	1M	3M	6M	12M
Absolute	(14)	(7)	(17)	(21)
Rel. to Nift	. ,	(2)	(23)	(37)
Relative p			( - )	(- )
275 ] Rs		•		% г 20
250				- 6
225 -	<b>h</b>			8
l V	M. /	any.		<b>.</b>
200 -	1 and	٩,		-22
175 -	v	1	Y W	<b>-</b> -36
150	21 Apr-21 J	lun-21 Ai	.ug-21 Oc	,, -50 t-21 Dec-21
	Bank (LHS		-	Nifty (RHS)
Source: Bloc	mberg			
This report is a following pers of the recomm	on(s) are re			
Anand Dan	na			
anand.dam	a@emka	ygloba	I.com	
+91 22 662	4 2480			

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

## Exhibit 1: Change in estimates

Y/E Mar (Rs mn)	Mar (Balma) FY22E				FY23E			FY24E		
	Earlier	Revised	% change	Earlier	Revised	% change	Earlier	Revised	% change	
Net income	63,383	63,246	-0.2%	66,889	66,941	0.1%	74,592	73,609	-1.3%	
PPOP	30,931	29,694	-4.0%	31,230	30,021	-3.9%	34,530	32,117	-7.0%	
PAT	1,211	-920	-176.0%	11,540	10,071	-12.7%	16,211	14,311	-11.7%	
EPS (Rs)	2.0	-1.5	-176.0%	19.3	16.8	-12.7%	27.1	23.9	-11.7%	
BV (Rs)	213.8	210.2	-1.7%	231.1	226.0	-2.2%	254.2	248.0	-2.4%	

Source: Emkay Research

## Key Financials (Standalone)

## Income Statement

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Net interest income	36,297	37,876	37,831	38,864	41,941
Other income	19,101	20,577	25,414	28,077	31,669
Fee income	15,231	14,358	19,046	21,903	25,626
Net income	55,398	58,453	63,246	66,941	73,609
Operating expenses	27,882	27,544	33,552	36,920	41,492
Pre provision profit	27,516	30,909	29,694	30,021	32,117
PPP excl treasury	25,921	28,036	25,296	26,062	28,555
Provisions	19,989	24,020	30,923	16,563	12,992
Profit before tax	7,528	6,889	(1,229)	13,458	19,125
Тах	2,471	1,810	(309)	3,387	4,814
Tax rate	33	26	25	25	25
Profit after tax	5,057	5,079	(920)	10,071	14,311

## **Balance Sheet**

Y/E Year End (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity	5,087	5,980	5,980	5,980	5,980
Reserves	100,670	120,598	119,725	129,198	142,313
Net worth	105,757	126,578	125,705	135,178	148,293
Deposits	578,121	731,213	772,003	852,184	963,219
Borrowings	162,767	104,959	87,515	83,139	87,296
Total liabilities	889,703	1,006,458	1,015,417	1,099,737	1,231,016
Cash and bank	64,150	67,047	70,399	73,919	77,615
Investments	181,497	232,300	226,236	237,092	254,632
Loans	580,190	586,224	598,020	657,566	758,904
Others	34,820	49,069	68,493	90,235	98,881
Total assets	889,776	1,006,500	1,015,417	1,099,737	1,231,016

## Key Ratios (%)

FY20	FY21	FY22E	FY23E	FY24E
4.5	4.3	4.0	4.0	4.0
2.3	2.2	2.5	2.7	2.7
1.8	1.5	1.9	2.1	2.2
3.3	2.9	3.3	3.5	3.6
2.4	2.5	3.1	1.6	1.1
0.9	0.7	(0.1)	1.3	1.6
0.3	0.2	0.0	0.3	0.4
0.6	0.5	(0.1)	1.0	1.2
5.6	4.4	(0.7)	7.7	10.1
3.6	4.3	4.9	4.6	4.1
2.0	2.1	1.8	1.4	1.3
FY20	FY21	FY22E	FY23E	FY24E
10.8	9.2	(1.5)	16.8	23.9
226.1	228.7	210.2	226.0	248.0
207.1	211.9	196.9	214.2	235.8
0.0	0.0	0.0	1.0	2.0
EV20	EV21	EV22E	EV23E	FY24E
				7.2
				0.7
				0.7
				3.2
J.Z	0.0	0.0	0.4	J.Z
	4.5 2.3 1.8 3.3 2.4 0.9 0.3 0.6 5.6 3.6 2.0 <b>FY20</b> 10.8 226.1 207.1	4.5 4.3   2.3 2.2   1.8 1.5   3.3 2.9   2.4 2.5   0.9 0.7   0.3 0.2   0.6 0.5   5.6 4.4   3.6 4.3   2.0 2.1   FY20   FY21   10.8 9.2   226.1 228.7   207.1 211.9   0.0 0.0   FY20   FY21   10.8 9.2   226.1 228.7   207.1 211.9   0.0 0.0   0.0   0.0   0.0   0.0   0.0   0.0   0.0   0.0   0.0   0.0   0.0   0.0   0.0   0.0		

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 11:54 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
NII	42.9	4.3	(0.1)	2.7	7.9
PPOP	41.8	12.3	(3.9)	1.1	7.0
PAT	(41.7)	0.4	(118.1)	(1,195.2)	42.1
Loans	6.8	1.0	2.0	10.0	15.4

Quarterly (Rs mn)	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22
NII	9,321	9,082	9,060	9,695	9,155
NIM(%)	4.3	4.2	4.2	4.4	4.1
PPOP	6,818	8,048	8,765	7,661	6,909
PAT	1,442	1,466	748	(4,605)	303
EPS (Rs)	2.83	2.45	1.25	(7.70)	0.51
Source: Company, Emkay Research					
Shareholding Pattern (%)	Nov-20	Dec-20	Mar-21	Jun-21	Sep-21
Promoters	-	-	-	-	-
FIIs	34.4	35.2	31.9	32.2	29.2
DIIs	20.2	21.9	22.7	20.7	22.3
Public and Others	45.3	42.9	45.4	47.1	48.5
Source: Capitaline					


Source: Capitaline

## RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
29-Oct-21	181	215	12m	Hold	Anand Dama
3-Aug-21	187	200	12m	Hold	Anand Dama
5-Apr-21	206	255	12m	Buy	Anand Dama
29-Jan-21	214	290	12m	Buy	Anand Dama
20-Jan-21	254	290	12m	Hold	Anand Dama
29-Oct-20	175	200	12m	Hold	Anand Dama
29-Jul-20	177	195	12m	Hold	Anand Dama
8-May-20	119	145	12m	Hold	Anand Dama
11-Apr-20	121	175	12m	Hold	Anand Dama
23-Jan-20	339	340	12m	Hold	Anand Dama
9-Dec-19	335	340	12m	Hold	Anand Dama
22-Oct-19	287	320	12m	Hold	Anand Dama
9-Oct-19	310	350	12m	Hold	Anand Dama
23-Sep-19	398	430	12m	Hold	Anand Dama
27-Aug-19	357	425	12m	Hold	Anand Dama
19-Jul-19	500	515	12m	Hold	Anand Dama
18-Apr-19	675	730	12m	Hold	Anand Dama
20-Mar-19	645	685	12m	Hold	Anand Dama

## RECOMMENDATION HISTORY CHART





Source: Company, Emkay Research

Change

## Emkay Alpha Portfolio – BFSI-Banks

#### EAP sector portfolio

Analyst: Anand Dama

**Contact Details** 

anand.dama@emkayglobal.com +91 22 6624 2480

Sector

## Banks

Analyst bio

Anand Dama is a CA, CPM (ICFAI) with total 13 years of research experience, in addition to 3 years in the finance/rating industry. His team currently covers 21 banks and 15 stocks in the NBFC/Insurance space.

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	Change vs last published EAP (bps)
BFSI-Banks	19.00	18.97	-0.1%	-3	100.00	
Axis Bank	1.86	1.91	3%	5	10.07	0
AU Small Finance Bank	0.24	0.21	-10%	-2	1.12	0
Bandhan Bank	0.18	0.15	-17%	-3	0.77	0
Bank of Baroda	0.15	0.15	-1%	0	0.80	0
Canara Bank	0.11	0.00	-100%	-11	0.00	0
City Union Bank	0.00	0.10	NA	10	0.53	0
DCB Bank	0.00	0.00	NA	0	0.00	0
Equitas Small Finance Bank	0.00	0.10	NA	10	0.52	0
Federal Bank	0.16	0.23	40%	7	1.22	0
HDFC Bank	6.35	6.34	0%	0	33.39	0
ICICI Bank	5.10	5.19	2%	9	27.31	0
Indian Bank	0.00	0.00	NA	0	0.00	0
Indusind Bank	0.53	0.61	16%	8	3.22	0
Karur Vysya Bank	0.00	0.00	NA	0	0.00	0
Kotak Mahindra Bank	2.34	2.01	-14%	-33	10.58	0
Punjab National Bank	0.11	0.00	-100%	-11	0.00	0
RBL Bank	0.00	0.07	NA	7	0.35	0
State Bank of India	1.78	1.90	7%	12	9.98	0
Ujjivan Small Finance Bank	0.00	0.00	NA	0	0.00	0
Union Bank of India	0.05	0.00	-100%	-5	0.00	0
Yes Bank	0.04	0.00	-100%	-4	0.00	0
Cash	0.00	0.03	NA	3	0.15	0

Source: Emkay Research

\* Not under coverage: Equal Weight

High Conviction/Strong Over Weight

## Sector portfolio NAV


	Base					Latest
	1-Apr-19	23-Dec-20	23-Jun-21	23-Sep-21	23-Nov-21	23-Dec-21
EAP - BFSI-Banks	100.0	103.1	118.0	129.5	127.8	121.0
BSE200 Neutral Weighted Portfolio (ETF)	100.0	101.5	115.6	126.7	125.4	118.6
*Performance measurement base date 1 <sup>st</sup> April 2019						

Source: Emkay Research

## Price Performance (%)

	1m	3m	6m	12m
EAP - BFSI-Banks	-5.3%	-6.6%	2.5%	17.4%
BSE200 Neutral Weighted Portfolio (ETF)	-5.4%	-6.4%	2.6%	16.9%
Source: Emkay Research				

## NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): <u>Nifty</u> Please see our model portfolio (Emkay Alpha Portfolio): <u>SMID</u>

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha This report is intended for team.emkay@wRestfolios Report and is updated on regular intervals 2021 11:54 AM

## **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.	
BUY	Over 15%	
HOLD	Between -5% to 15%	
SELL	Below -5%	
SELL	Below -5%	

Completed Date: 27 Dec 2021 02:37:20 (SGT) Dissemination Date: 27 Dec 2021 02:38:20 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of December 27, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of December 27, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the December 27, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services form securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the December 27, 2021

RESTRICTIONS ON DISTRIBUTION		
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.	
Australia	This report is not for distribution into Australia.	
Hong Kong	This report is not for distribution into Hong Kong.	
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.	
Malaysia	This report is not for distribution into Malaysia.	
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.	
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.	
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.	
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.	
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.	
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.	
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.	

## Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 11:54 AM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.